Formycon AG (FYB) - Total Liabilities

Latest as of December 2025: €340.39 Million EUR ≈ $397.95 Million USD

Based on the latest financial reports, Formycon AG (FYB) has total liabilities worth €340.39 Million EUR (≈ $397.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Formycon AG - Total Liabilities Trend (2009–2025)

This chart illustrates how Formycon AG's total liabilities have evolved over time, based on quarterly financial data. See Formycon AG (FYB) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Formycon AG Competitors by Total Liabilities

The table below lists competitors of Formycon AG ranked by their total liabilities.

Company Country Total Liabilities
Sphera Franchise Group SA MiFID Eligible Security
RO:SFG
Romania RON651.12 Million
Yuen Foong Yu Consumer Prod
TW:6790
Taiwan NT$4.66 Billion
Ascencio (D)
BR:ASCE
Belgium €367.49 Million
First Bancorp Inc
NASDAQ:FNLC
USA $2.88 Billion
BRASI.CIA BRAS.D.PROP.ADR
F:52BA
Germany €1.66 Billion
Guangdong Liantai Environmental Protection Co Ltd
SHG:603797
China CN¥6.39 Billion
Hangzhou Huaxing Chuangye Communication Technology Co Ltd
SHE:300025
China CN¥305.37 Million
Incar Financial Service Co. Ltd.
KQ:211050
Korea ₩696.18 Billion

Liability Composition Analysis (2009–2025)

This chart breaks down Formycon AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FYB market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.33 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Formycon AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Formycon AG (2009–2025)

The table below shows the annual total liabilities of Formycon AG from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 €340.39 Million
≈ $397.95 Million
+9.85%
2024-12-31 €309.87 Million
≈ $362.27 Million
-20.06%
2023-12-31 €387.61 Million
≈ $453.16 Million
-22.03%
2022-12-31 €497.12 Million
≈ $581.18 Million
+3253.46%
2021-12-31 €14.82 Million
≈ $17.33 Million
+96.00%
2020-12-31 €7.56 Million
≈ $8.84 Million
+41.51%
2019-12-31 €5.34 Million
≈ $6.25 Million
-16.28%
2018-12-31 €6.38 Million
≈ $7.46 Million
+20.82%
2017-12-31 €5.28 Million
≈ $6.18 Million
+23.03%
2016-12-31 €4.29 Million
≈ $5.02 Million
+88.68%
2015-12-31 €2.28 Million
≈ $2.66 Million
-30.28%
2014-12-31 €3.26 Million
≈ $3.82 Million
+2.22%
2013-12-31 €3.19 Million
≈ $3.73 Million
-5.48%
2012-12-31 €3.38 Million
≈ $3.95 Million
+639.50%
2011-12-31 €457.00K
≈ $534.28K
+118.40%
2010-12-31 €209.25K
≈ $244.64K
+243.03%
2009-12-31 €61.00K
≈ $71.32K
--

About Formycon AG

XETRA:FYB Germany Biotechnology
Market Cap
$404.97 Million
€346.39 Million EUR
Market Cap Rank
#14372 Global
#1439 in Germany
Share Price
€19.60
Change (1 day)
-1.71%
52-Week Range
€16.82 - €30.60
All Time High
€92.50
About

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more